Jan 11 2010
A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company,
today announced it has received the final milestone payment of $2.5
million from an affiliate of Paul Capital Healthcare. The payment
represents a milestone payment that recently became payable to the
Company under the agreement that the Company entered into on October 1,
2005 to sell its royalty rights to Retin-A Micro® and Carac® to an
affiliate of the Paul Royalty Fund.
“We are delighted to receive this non-dilutive funding from Paul Capital
Healthcare as we continue to pursue the approval of our first product,
APF530, for the prevention of chemotherapy-induced nausea and vomiting
in cancer patients”
"We are delighted to receive this non-dilutive funding from Paul Capital
Healthcare as we continue to pursue the approval of our first product,
APF530, for the prevention of chemotherapy-induced nausea and vomiting
in cancer patients," said Ronald Prentki, A.P. Pharma’s president and
chief executive officer.
http://www.appharma.com/
Psilocybin and mindfulness offer new hope for depressive healthcare workers